ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Edgewise Therapeutics Inc

Edgewise Therapeutics Inc (EWTX)

21.78
-0.18
(-0.82%)
At close: July 23 4:00PM
21.78
0.00
( 0.00% )
After Hours: 4:25PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
21.78
Bid
21.01
Ask
22.84
Volume
638,776
21.73 Day's Range 22.225
5.12 52 Week Range 23.50
Market Cap
Previous Close
21.96
Open
22.00
Last Trade
1
@
21.25
Last Trade Time
16:06:49
Financial Volume
$ 14,068,185
VWAP
22.0237
Average Volume (3m)
784,562
Shares Outstanding
93,398,767
Dividend Yield
-
PE Ratio
-20.31
Earnings Per Share (EPS)
-1.07
Revenue
-
Net Profit
-100.16M

About Edgewise Therapeutics Inc

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Edgewise Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker EWTX. The last closing price for Edgewise Therapeutics was $21.96. Over the last year, Edgewise Therapeutics shares have traded in a share price range of $ 5.12 to $ 23.50.

Edgewise Therapeutics currently has 93,398,767 shares outstanding. The market capitalization of Edgewise Therapeutics is $2.05 billion. Edgewise Therapeutics has a price to earnings ratio (PE ratio) of -20.31.

EWTX Latest News

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare...

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker – – Positive interim topline data for DUNE trial of sevasemten...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.42-6.1206896551723.223.417320.563535821.6161308CS
45.0530.185295875716.7323.516.52107167419.79073519CS
124.9329.258160237416.8523.515.8778456218.86846832CS
265.7535.870243293816.0323.514.976849817.92679485CS
5214.11183.9634941337.6723.55.1260964014.70398996CS
1561.276.1921014139420.5123.55.1235777313.32756967CS
260-5.22-19.33333333332740.495.1234424514.17464683CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALLRAllarity Therapeutics Inc
$ 0.2799
(68.72%)
14.96M
SLNASelina Hospitality PLC
$ 0.0315
(21.15%)
10.5M
CJETChijet Motor Company Inc
$ 4.60
(13.58%)
70.33k
DRMADermata Therapeutics Inc
$ 1.45
(11.56%)
72.86k
AQMSAqua Metals Inc
$ 0.36
(10.57%)
789
VSTMVerastem Inc
$ 2.82
(-21.45%)
170.91k
RGCRegencell Bioscience Holdings Ltd
$ 12.39
(-18.22%)
43.97k
WRNTWarrantee Inc
$ 0.32
(-17.91%)
53.24k
EZFLEzFill Holdings Inc
$ 2.09
(-15.90%)
2.31k
OABIOmniAb Inc
$ 4.00
(-15.61%)
4.57k
ALLRAllarity Therapeutics Inc
$ 0.2799
(68.72%)
14.96M
SLNASelina Hospitality PLC
$ 0.0315
(21.15%)
10.5M
TSLATesla Inc
$ 238.32
(-3.27%)
6.01M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.83
(-6.32%)
4.51M
HOLOMicroCloud Hologram Inc
$ 0.6066
(3.16%)
4.17M

EWTX Discussion

View Posts
Whalatane Whalatane 2 weeks ago
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
JPMorgan Raises Price Target on Edgewise Therapeutics to $30 From $27, Maintains Overweight Rating
Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
I used to own CYTK and think I sold it because of this ...from the CYTK trial Core echocardiographic left ventricular ejection fraction (LVEF) was observed to be
👍️0
rosemountbomber rosemountbomber 2 weeks ago
Thanks for all the info Kiwi. Been a long busy day so I will have to do some more DD on this one but it appears to be promising. The fact that the drug does not have the ejection fraction problem is important in my books. This could be another CYTK. My one worry is that it has had quite a sunup in 2024 already and hopefully not everything is priced in yet.
👍️0
Whalatane Whalatane 2 weeks ago
Before EWTX there was MYOK in HCM ...bt out at $225 a share .
EWTX hired some MYOK folks after this buyout
https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx

Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
Watch for a technical breakout as market anticipates the P1 HCM data
Mavacamten is I think the drug currently approved for HCM ( heart contractibility problems ) . The problem is it lowers ejection fraction ( the pump out movement ) to low for about 20% of the patients so it has a REMS rating limiting its use.
EWTX EDG-5506 works the same way but without the ejection fraction problem

Data due this Qt ( Q3 )

Kiwi
👍️0
Whalatane Whalatane 3 weeks ago
Piper Sandler analyst Yasmeen Rahimi maintains Edgewise Therapeutics ( EWTX ) with a Overweight and maintains $48 price target.

Kiwi
👍️0
Whalatane Whalatane 3 weeks ago
RMB. some HCM P1 data due late Aug / Sept ...
Kiwi
👍️0
Whalatane Whalatane 3 months ago
RMB. I think we are due for data from the LYNX trial
, Edgewise Therapeutics expects to report 3-month data from the Phase 2 LYNX trial for EDG-5506 in the second quarter of 2024. The LYNX trial is a Phase 2 dose-ranging study to evaluate the safety and efficacy of EDG-5506 in patients with Duchenne muscular dystrophy (DMD).

New high today

Kiwi
👍️0
Whalatane Whalatane 3 months ago
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target

I'm surprised stock didn't do better on recent P 2 data ...which was supposed to " de risk " their program

Kiwi
👍️0
Whalatane Whalatane 5 months ago
BOULDER, Colo., February 13, 2024--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy (Becker).
The FDA previously granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designation for the treatment of Becker.
---------------
Kiwi
👍️0
Whalatane Whalatane 6 months ago
RMB. for what its worth ...both stocks I mentioned are now "technically " over bought ...so some pull back near term is likely
jmo
Kiwi
👍️0
Whalatane Whalatane 6 months ago
RMB. EWTX up 21 % in past week. ( since your post )
VERA ,,,which I think U saw me posting on at the AUPH board ...up 28%
Both I think at 52 wk highs

Usually I find it best to initiate small positions ...follow ..and then if the data still looks good , add on a pullback due to some unrelated event .
Both of these Co's have a lot of data coming out in 2024

Kiwi
👍️0
Monksdream Monksdream 6 months ago
EWTX new 52 week high
👍️0
Monksdream Monksdream 6 months ago
EWTX new 52 week high
👍️0
Whalatane Whalatane 6 months ago
Jonathan C. Fox, M.D., Ph.D., FACC
DIRECTOR
Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.


MyoKardia was bt out by BMS
Kiwi
👍️0
Whalatane Whalatane 6 months ago
RMB. You might look at TNYA also ...similar space. Ceo is one very smart guy and is backed by the Column group ( smart team )
Early days tho .
EWTX is far further along

BOTH are high speculative ...so.....etc
Kiwi
👍️0
rosemountbomber rosemountbomber 6 months ago
Kiwi you have peaked my interest in EWTX

The opportunity seems to be here, but I will try to exhibit something I rarely do, namely; patience.

It has risen a bunch in a short time and I hope to pick some up after a bit of a retracement.
👍️0
Whalatane Whalatane 6 months ago
EWTX. Best Co I've seen in this area since MYOK ...which was eventually bt out .
Kiwi
👍️0
Whalatane Whalatane 6 months ago
Impressive presentation at JPM 2024 . Fast tracked but the earliest they are likely to have an approved drug is early 2026...if all goes well
Kiwi
👍️0
goodfree goodfree 3 years ago
Looks like we may have hit the bottom lol
👍️0
goodfree goodfree 3 years ago
Jumped in at $30 today hope we have a good run here
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) gained 87.5% to close at $30.00 after pricing its IPO at $16 per share.
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The Company is principally focused on discovering, developing and commercializing treatments for rare muscle disorders. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The Company's lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The Company's research programs include EDG-6289, EDG-002 and EDG-003.
👍️0

Your Recent History

Delayed Upgrade Clock